Immunotherapy in surgically resectable non-small cell lung cancer

Area of Science:

• Oncology
• Immunology
• Thoracic Surgery

Background:

• Surgical resection is standard for early-stage non-small cell lung cancer (NSCLC), but recurrence rates remain high.
• Adjuvant or neoadjuvant chemotherapy offers a modest survival benefit (approx. 5% at 5 years) when combined with surgery.
• Recent advancements in cancer immunotherapy have significantly improved outcomes in metastatic lung cancer.

Purpose of the Study:

• To review the rationale for using immunotherapy in resectable non-small cell lung cancer.
• To outline current research strategies investigating immunotherapy's role in early-stage NSCLC.

Main Methods:

• Review of current literature on immunotherapy, chemotherapy, and surgical treatments for NSCLC.
• Analysis of research strategies exploring the integration of immunotherapy in resectable NSCLC.
• Focus on monoclonal antibodies targeting programmed death 1 (PD-1) and its ligand (PD-L1).

Main Results:

• Immunotherapy, particularly PD-1/PD-L1 inhibitors, has demonstrated efficacy in metastatic lung cancer.
• The potential for immunotherapy to enhance outcomes in the neoadjuvant or adjuvant setting for resectable NSCLC is under active investigation.
• Current research aims to establish the optimal role and timing of immunotherapy in early-stage NSCLC treatment paradigms.

Conclusions:

• Immunotherapy represents a promising frontier for improving survival in early-stage non-small cell lung cancer.
• Further research is crucial to define the efficacy and safety of immunotherapy in combination with surgery and/or chemotherapy for resectable NSCLC.
• Investigating immunotherapy in the neoadjuvant and adjuvant settings is key to potentially reducing recurrence rates and improving long-term outcomes.